Sign Up
Stories
Mineralys Therapeutics to Present at Biotech Conference
Share
Biopharma Innovations in Obesity and Mus...
Diabetes Drug Markets' Growth and Domina...
ANJESO Drug Insight and Market Forecast
Aligos Therapeutics Financial Disclosure
Exclusive License for Velphoro® in China
Overview
API
Mineralys Therapeutics, a biotech company, will participate in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference. The company is focused on developing medicines to treat hypertension, chronic kidney disease, and diseases driven by abnormally elevated aldosterone, with its initial product candidate being an orally administered aldosterone synthase inhibitor.
Ask a question
How does the focus on aldosterone synthase inhibitors contribute to the broader landscape of biotech innovation and drug development?
How might the presentation at the biotech conference impact Mineralys Therapeutics' market position and future collaborations?
What challenges and opportunities does the company face in developing medicines for hypertension and chronic kidney disease?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage